Patients with suspected allergic reactions to COVID‐19 vaccines can be safely revaccinated after diagnostic work‐up
| Autor: | Torbjorn Kabel Georgsen, Henrik Fomsgaard Kjaer, Helene Marlies Rasmussen, Trine Holm Rasmussen, Charlotte G. Mortz, Carsten Bindslev-Jensen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Drug medicine.medical_specialty Allergy Coronavirus disease 2019 (COVID-19) media_common.quotation_subject Immunology Basophil COVID‐19 vaccine medicine Immunology and Allergy media_common excipients business.industry Research Incidence (epidemiology) RC581-607 allergy medicine.disease Dermatology revaccination Work-up Vaccination medicine.anatomical_structure diagnostic test Immunologic diseases. Allergy business COVID-19 vaccine Anaphylaxis |
| Zdroj: | Clinical and Translational Allergy, Vol 11, Iss 5, Pp n/a-n/a (2021) Rasmussen, T H, Mortz, C G, Georgsen, T K, Rasmussen, H M, Kjaer, H F & Bindslev-Jensen, C 2021, ' Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up ', Clinical and Translational Allergy, vol. 11, no. 5, e12044 . https://doi.org/10.1002/clt2.12044 Clinical and Translational Allergy |
| ISSN: | 2045-7022 |
| Popis: | Background: When initiating the Danish vaccination program against COVID-19, the incidence of anaphylaxis was estimated to be 10 times higher compared to other virus-based vaccines. In this study, we present data on patients referred with suspected allergic reactions to COVID-19 vaccines. The main purpose of the study is to investigate the incidence and severity of the allergic reactions, and to evaluate the safety of revaccination. Methods: All patients in the region of Southern Denmark with case histories of allergic reactions to COVID-19 vaccines in a defined period are included in this study. Diagnostic work up consisted of a detailed case history, evaluation of Brighton level of diagnostic certainty and World Allergy Organization grade of anaphylaxis and skin prick testing- and basophil histamine release testing with COVID-19 vaccines and relevant drug excipients. Patients were revaccinated at the Allergy Center when possible. Results: Sixty-one patients are included in this study. In 199,377 doses administered, nine patients fulfilled the criteria of anaphylaxis when using the Brighton Criteria (incidence being 45 per million). Of 55 patients with reactions to the first dose, 52 patients were revaccinated without adverse reactions. We found no proven cases of immediate anaphylaxis due to COVID-19 vaccines. By skin prick test, we diagnosed three patients with drug excipient allergy and further a patient with mastocytosis was found. Conclusions: Anaphylactic reactions to COVID-19 vaccines are rare and the incidence is similar to what is seen with other virus-based vaccines. Revaccination is safe in the majority of patients; however, allergological evaluation is important since some prove to have drug excipient allergy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text